Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry
British Journal of Dermatology · 2024
DOI: 10.1093/bjd/ljad382 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Juan José Lluch-Galcerá und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, IGTP. Badalona, Barcelona, Spain. Hauptthemen laut MEDLINE: Psoriasis, Biological Products. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Fundación Piel Sana of the Academia Española de Dermatología y Venereología, Spanish Medicines and Health Products Agency, Agencia Española de Medicamentos y Productos Sanitarios.
Abstract (Originalsprache)
Background
Safety is an important consideration in decisions on treatment for patients with moderate-to-severe psoriasis and the study of drug safety is the main purpose of the BIOBADADERM registry. The combination of a biologic agent and a conventional systemic drug [generally methotrexate (MTX)] is a common treatment in clinical practice. However, there is a paucity of evidence from real-world practice on the safety of such combination regimens in the treatment of psoriasis.
Objectives
The primary objective of this study was to ascertain whether the use of regimens combining biologic drugs with MTX in the management of moderate-to-severe psoriasis increases the risk of adverse events (AEs) or serious AEs (SAEs). We compared monotherapy using tumour necrosis factor (TNF), interleukin (IL)-17 and IL-23 inhibitors with the use of the same drugs in combination with MTX.
Methods
Using data from the BIOBADADERM registry, we compared biologic monotherapies with therapies that were combined with MTX. We estimated adjusted incidence rate ratios (aIRR) using a random effects Poisson regression with 95% confidence intervals for all AEs, SAEs, infections and serious infections and other AEs by system organ class.
Results
We analysed data from 2829 patients and 5441 treatment cycles, a total of 12 853 patient-years. The combination of a biologic with MTX was not associated with statistically significant increases in overall risk of AEs or SAEs in any treatment group. No increase in the total number of infections or serious infections in patients receiving combined therapy was observed for any group. However, treatment with a TNF inhibitor combined with MTX was associated with an increase in the incidence of gastrointestinal AEs (aIRR 2.50, 95% CI 1.57–3.98; P < 0.002).
Conclusions
The risk of AEs and SAEs was not significantly increased in patients with moderate-to-severe psoriasis receiving different classes of biologic drugs combined with MTX compared with those on biologic monotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, IGTP. Badalona, Barcelona, Spain.
- Departament de Medicina, Universitat Autonoma de Barcelona (UAB), Barcelona, Spain.
- Department of Dermatology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Islas Canarias, Spain.
- Department of Dermatology, Hospital Universitario 12 de Octubre, Universidad Complutense, Madrid, Spain.
- Department of Dermatology, Hospital Universitario y Politécnico La Fe, Valencia,Spain.
- Department of Dermatology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria de La Princesa (IIS-LP), Madrid,Spain.
ORCID-Profile: Juan José Lluch-Galcerá, Jose Manuel Carrascosa, Raquel Rivera-Díaz, Josep Riera-Monroig
Förderung
- Fundación Piel Sana of the Academia Española de Dermatología y Venereología
- Spanish Medicines and Health Products Agency
- Agencia Española de Medicamentos y Productos Sanitarios
- Abbott/AbbVie
- Almirall
- Amgen
- Biogen
- Boehringer Ingelheim
Zitieren
APA
Lluch-Galcerá, J. J., Carrascosa, J. M., González-Quesada, A., Rivera-Díaz, R., Sahuquillo-Torralba, A., Llamas-Velasco, M., Gómez-García, F. J., Herrera-Acosta, E., de la Cueva, P., Baniandrés-Rodríguez, O., Lopez-Estebaranz, J. L., Belinchón, I., Ferrán, M., Mateu, A., Rodríguez, L., Riera-Monroig, J., Abalde-Pintos, M. T., Carretero, G., García-Donoso, C., …, & García-Doval, I. (2024). Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad382
Vancouver
Lluch-Galcerá JJ, Carrascosa JM, González-Quesada A, Rivera-Díaz R, Sahuquillo-Torralba A, Llamas-Velasco M, et al. Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljad382
BibTeX
@article{LluchGalcer2024,
author = {Lluch-Galcerá, Juan José and Carrascosa, Jose Manuel and González-Quesada, Alicia and Rivera-Díaz, Raquel and Sahuquillo-Torralba, Antonio and Llamas-Velasco, Mar and Gómez-García, Francisco José and Herrera-Acosta, Enrique and de la Cueva, Pablo and Baniandrés-Rodríguez, Ofelia and Lopez-Estebaranz, Jose Luis and Belinchón, Isabel and Ferrán, Marta and Mateu, Almudena and Rodríguez, Lourdes and Riera-Monroig, Josep and Abalde-Pintos, M Teresa and Carretero, Gregorio and García-Donoso, Carmen and Pujol-Marco, Conrad and Del Alcázar, Elena and Santamaría-Domínguez, Cristina and Suárez-Pérez, Jorge Alonso and Nieto-Benito, Lula María and Ruiz-Genao, Diana Patricia and Salgado-Boquete, Laura and Descalzo, Miguel Ángel and García-Doval, Ignacio},
title = {Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry},
journal = {British Journal of Dermatology},
year = {2024},
doi = {10.1093/bjd/ljad382}
}
EUVIMED